H.R. 2214 119th Congress
DRUG Act
- Health
- Sponsor: Rep. Miller-Meeks, Mariannette [R-IA-1]
- Congress.gov ↗
Latest action, Mar 18, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
6 cosponsors
Sponsored by Rep. Miller-Meeks, Mariannette [R-IA-1] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Referred to: House: Education and Workforce Committee; House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
All 25 of 28 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| CVS HEALTH (AND SUBSIDIARIES) | 7 | $18.6M | Q1 2025 | Q3 2026 | yes | |
| ELEVANCE HEALTH, INC. | 7 | $12.9M | Q1 2025 | Q3 2026 | yes | |
| EMD SERONO INC | 7 | $5.4M | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $15.5M | Q1 2025 | Q3 2026 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $2.2M | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS | 7 | $14.0M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | EMERGENT STRATEGIES | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $23.2M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | ADVANCED POLICY CONSULTING, LLC | 7 | $280K | Q1 2025 | Q3 2026 | yes |
| SOUTHEAST GEORGIA HOSPITAL SYSTEM | CAROL G HOLLADAY & ASSOCIATES | 6 | $120K | Q1 2025 | Q2 2026 | yes |
| PFIZER INC. | TODD STRATEGY GROUP | 5 | $0 | Q4 2025 | Q2 2026 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 5 | $11.9M | Q1 2025 | Q1 2026 | yes | |
| AMGEN INC | 4 | $13.3M | Q1 2025 | Q3 2025 | yes | |
| GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICS | HOOPER, LUNDY & BOOKMAN, P.C. | 4 | $40K | Q1 2025 | Q3 2025 | yes |
| PRIME THERAPEUTICS | STUMPTOWN STRATEGIES | 4 | $0 | Q1 2025 | Q3 2025 | yes |
| PRIME THERAPEUTICS | 4 | $720K | Q1 2025 | Q3 2025 | yes | |
| PRIME THERAPEUTICS | GOVERNMENT COUNSEL, LLC | 4 | $0 | Q1 2025 | Q3 2025 | yes |
| AMERICAN PHARMACIES, INC. | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 3 | $180K | Q4 2025 | Q1 2026 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | RYAN COSTELLO STRATEGIES | 3 | $0 | Q1 2025 | Q3 2025 | — |
| TAKEDA PHARMACEUTICALS AMERICA INC | 3 | $2.5M | Q1 2025 | Q3 2025 | yes | |
| YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | TIDAL BASIN ADVISORS, INC. | 3 | $10K | Q4 2025 | Q3 2025 | yes |
| PFIZER INC. | 2 | $6.6M | Q2 2025 | Q3 2025 | yes |